Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.

SPLS delivers comparable safety outcomes on obese, nonobese colorectal cancer patients

23 Aug 2017

There is no apparent difference in safety outcomes of single-port laparoscopic surgery (SPLS) between obese and nonobese colorectal cancer patients, a new retrospective cohort study has found.

“Hence, SPLS can be safely recommended for colorectal cancer in obese patients if the surgeon is experienced. Nevertheless, the technique used warrants further investigation, and a large-scale prospective study is required,” researchers said.

The study included 323 colorectal cancer patients who received SPLS. Only those ≥18 years of age and with malignancies in the colon or rectum were included. Exclusion criteria were emergency SPLS and resection of other organs.

Participants were stratified into three according to BMI: nonobese (BMI <25.0 kg/m2; n=2323), obese I (BMI 25.0 to 29.9 kg/m2; n=80) and obese II (BMI ≥30.0 kg/m2; n=10). Outcomes were 30-day reoperation, 30-day mortality and adverse events within 30 days of operation.

The mean operation time in nonobese patients (269.2±110.2 minutes) was not significantly different than in obese I (270.4±81.7 minutes) and obese II (342.8±182.6 minutes; p=0.247) patients. There were also no significant differences in estimated surgical blood loss among the three groups (277.7±208.5 vs 260.5±209.2 vs 387.0±278.3, respectively; p=0.205).

Mortality (p=0.404) and conversion (p=0.937) rates were also comparable in nonobese (0.9 percent for both), obese I (0 and 1.3 percent, respectively) and obese II (0 percent for both) patients.

Time to flatus was significantly different among the three groups (2.2±1.7 vs 2.0±1.8 vs 3.0±1.6 for nonobese, obese I and obese II patients, respectively; p=0.04).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.